A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study.
Barberio B, Cingolani L, Canova C, Barbieri G, Sablich R, Urbano MT, Bertani L, Costa F, Bodini G, Demarzo MG, Ferronato A, Buda A, Melatti P, Massimi D, Savarino EV, Zingone F.
Barberio B, et al. Among authors: buda a.
Therap Adv Gastroenterol. 2021 Jul 20;14:17562848211031420. doi: 10.1177/17562848211031420. eCollection 2021.
Therap Adv Gastroenterol. 2021.
PMID: 34349836
Free PMC article.